Meeting
2022 ASCO Annual Meeting
Real-world data to enable large-scale assessment of WHO CNS5 glioma classification.
Authors
Joshuah Kapilivsky
Tempus Labs, Inc., Chicago, IL
Joshuah Kapilivsky , Kimmo J. Hatanpaa , Kabir Manghnani , Timothy J. Taxter , Martin Stumpe , Justin Guinney , Kyle A. Beauchamp , Robin Arthur Buerki , Alessandra Breschi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2018)
DOI
10.1200/JCO.2022.40.16_suppl.2018
Abstract #
2018
Poster Bd #
356
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
First Author: Oriol Mirallas
Poster
2018 ASCO Annual Meeting
Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.
First Author: Lee A. Albacker
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
Poster
2020 ASCO Virtual Scientific Program
Clinical, radiologic & prognostic profile of IDH wild type diffuse astrocytic glioma with molecular features of glioblastoma.
First Author: Oluwatosin Akintola